Longevity biotechnology
A review connecting artificial intelligence, biomarkers, geroscience and clinical applications for healthy longevity.
Small by design.
Ambitious by nature.
We are 199 Biotechnologies. A pioneering team advancing partial reprogramming, with a mission to bring reprogramming and gene therapies within more people’s reach.
Boris Djordjevic.
Founder & CEO.
199 began with a conviction: partial reprogramming could open a new chapter in how we approach aging and disease.
Founded by Boris Djordjevic, we carry that conviction into our work today: advancing the science toward human application and democratising access to reprogramming and gene therapies.
We are a small team built for a long pursuit. Our next programmes are taking shape in stealth, connecting pioneering research with the work of bringing it to people.
Research.
And the conversation around it.
Boris’s work connects biotechnology company building with published research and discussion of how aging science reaches people.
Translating to clinics
The ARDD programme lists Boris Djordjevic of 199 Biotechnologies as a speaker and session moderator on 29 August 2024.
A founder’s view of cellular reprogramming
Boris discusses the company’s approach to reprogramming and the work of translating laboratory research into therapies.
The people behind 199.
Antonia Schultze-Mosgau
Strategic Advisor
Longevity entrepreneur and scientist; Oxford All-Innovate award winner.
Dr. Avi Roy
Strategic Advisor
Biomedical scientist working across longevity research and biotechnology.
Dr. Qinghua Lyu
Chief Technical Officer
Drug development expert leading chemical sciences and senolytic programmes.
Zico Yip
Chief Operating Officer
Operations across labs and manufacturing, fundraising and investment.
We work closely with Triple Helix and Dr. Patrick Sewell as we pursue the next chapter in reprogramming and gene therapies.
Meet Triple HelixEarly conviction. Long-term ambition.
A focused company building toward human application and wider access.
199 brings pioneering roots in partial reprogramming to a new chapter in human application and gene therapies. Our next programmes are being developed in stealth.
We welcome investors who share our conviction in this science and want to help shape its future. Join us to discuss our programmes, development priorities and opportunities to build with 199.
Discuss investment